The FDA ( Food and Drug Administration ) has granted accelerated approval to Zepzelca ( Lurbinectedin ) for adult patients with metastatic small cell lung cancer ( SCLC ) with disease progression on or after Platinum-based chemotherapy.
Efficacy was demonstrated in the PM1183-B-005-14 trial, a multicenter open-label, multi-cohort study enrolling 105 patients with metastatic SCLC who had disease progression on or after Platinum-based chemotherapy.
Patients received Lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity.
The main efficacy outcome measures were confirmed overall response rate ( ORR ) determined by investigator assessment using RECIST 1.1 and response duration.
Among the 105 patients, the ORR was 35% ( 95% CI: 26%, 45% ), with a median response duration of 5.3 months ( 95% CI: 4.1, 6.4 ).
The ORR as per independent review committee was 30% ( 95% CI: 22%, 40% ) with a median response duration of 5.1 months ( 95% CI: 4.9, 6.4 ).
The most common adverse reactions ( greater than or equal to 20% ), including laboratory abnormalities, were myelosuppression, fatigue, increased creatinine, increased alanine aminotransferase, increased glucose, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.
The recommended Lurbinectedin dose is 3.2 mg/m2 every 21 days. ( Xagena )
Source: FDA, 2020